



## AddLife announces the final terms of the rights issue

AddLife AB (publ), reg. no. 556995-8126 (the "Company" or "AddLife"), announced on 26 November 2018 that the board of directors resolved, subject to the subsequent approval from the extraordinary general meeting on 20 December 2018, on a new issue of about SEK 500 million to raise capital to continue to pursue AddLife's growth strategy and to carry out additional strategic acquisitions. Today the board of directors of AddLife announces the final terms of the rights issue.

### Adviser for the rights issue

Handelsbanken Capital Markets is financial adviser in connection with the rights issue. Advokatfirman Delphi is legal adviser.

To view this press release and the information content in its entirety please visit:

<https://www.add.life/investerare/finansiella-rapporter-och-presentationer/foretradesemission-2019/>

### For further information, please contact:

Kristina Willgård, CEO, [kristina.willgard@add.life](mailto:kristina.willgard@add.life), +46 (0)705 10 12 23

Martin Almgren, CFO, [martin.almgren@add.life](mailto:martin.almgren@add.life), +46 (0)702 28 15 45

*AddLife is an independent player in the Life Science industry that offers high-quality products, services and advice to both the private and public sector, mainly in the Nordic region. AddLife has about 900 employees in some 40 operating subsidiaries. The group currently has net sales of around SEK 2.5 billion. The AddLife share is listed on Nasdaq Stockholm.*

*This information is information that AddLife AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, on 23 January 2019 at 14:00 p.m. (CET).*